Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Trabectedin (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms RETRO-ROC
- 10 Aug 2016 Planned End Date changed from 1 Jun 2015 to 1 Dec 2016.
- 10 Aug 2016 Planned primary completion date changed from 1 May 2015 to 1 Dec 2016.
- 10 Aug 2016 Status changed from not yet recruiting to active, no longer recruiting.